Marissa Johnson
Physician Assistant · Austin, TXNPI 1629474028
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 204 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Medtronic at 35.0% of the total. Among physician assistant clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $30.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$1K
- Spinal Simplicity, LLC$600
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$460
- AbbVie$424
- Lundbeck LLC$265
- plus $1K from 21 others
What the payments were for
- Food & beverage$6,188100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 40 | $2,168 |
| Abbott | 14 | $1,012 |
| Spinal Simplicity, LLC | 31 | $600 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $460 |
| AbbVie | 21 | $424 |
| Lundbeck LLC | 12 | $265 |
| Collegium Pharmaceutical, Inc. | 12 | $250 |
| Pfizer | 12 | $167 |
| Relievant Medsystems, Inc. | 1 | $107 |
| Si-bone, Inc. | 3 | $82 |
| Ultragenyx Pharmaceutical Inc. | 3 | $64 |
| Lilly USA, LLC | 3 | $61 |
| Azurity Pharmaceuticals, Inc. | 3 | $56 |
| Kyowa Kirin, Inc. | 2 | $52 |
| Boston Scientific | 3 | $50 |
| Johnson & Johnson | 2 | $48 |
| Vertex | 2 | $44 |
| SPR Therapeutics, Inc | 1 | $41 |
| Saluda Medical Americas, Inc. | 1 | $39 |
| Averitas Pharma Inc. | 2 | $34 |
| Impel Pharmaceuticals LLC | 2 | $33 |
| Convatec Inc. | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| IBSA Pharma Inc. | 1 | $21 |
| MML US, Inc. | 1 | $19 |
| Protega Pharmaceutials Inc | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$858
- VANTA ADAPTIVESTIM$622
- Intracept$428
- HA MINUTEMAN G3-R$250
- INTELLIS ADAPTIVESTIM$212
- SYNCHROMEDII$196
- QULIPTA$124
- UBRELVY$124
How this compares
$6,188 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MovantikNaloxegol Oxalate | 11 | $5,745 |
| Gabapentin | 288 | $4,298 |
| Diclofenac Sodium | 74 | $2,847 |
| Duloxetine Hcl | 94 | $1,495 |
| Tizanidine Hcl | 88 | $1,273 |
| Cyclobenzaprine Hcl | 100 | $1,015 |
| Lidocaine | 14 | $946 |
| Chlorzoxazone | 27 | $878 |
| Methocarbamol | 65 | $529 |
| Celecoxib | 26 | $381 |
| Amitriptyline Hcl | 26 | $282 |
| Baclofen | 13 | $275 |
| Meloxicam | 48 | $176 |
| Ibuprofen | 15 | $113 |
| Methylprednisolone | 11 | $81 |
Paid to pharmacies, not to this prescriber.
Other physician assistant in Austin
- Selina SantosAustin$543K
- Stephen IngramAustin$215K
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Matthew BrunoMcKinney$538K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.